Antiproteinuria Effect of Calcitriol in Patients With Chronic Kidney Disease and Vitamin D Deficiency: A Randomized Controlled Study.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Compared with healthy populations, patients with CKD may have lower serum levels of 1,25-dihydroxy vitamin D (1,25-(OH)2 D) and 25-hydroxy vitamin D (25-(OH) D).

Who Took Part

According to the abstract, 60 patients were involved.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

The researchers conducted a nonblinded and non-placebo-controlled study.

Change in the urine protein/creatinine ratio (uPCR) was the primary endpoint in this study.

What Was Measured

PubMed files the paper under topics including Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Calcitriol, Proteinuria, Renal Insufficiency, Chronic, Vitamin D and Vitamin D Deficiency.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 60 patients.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.